A combined therapy approach involving HDAC inhibitors and bromodomain protein (BRD) inhibitors has been identified based on a transcriptome and subsequent gene set enrichment analysis in patient-derived xenograft and stem-like glioblastoma cells. This evidence concerns the gene HDAC9 and glioblastoma.